Heparanase inhibitors that prevent the release of heparan sulfate side chains have been tested in pre-clinical and clinical settings, and reduce tumor metastasis by maintaining ECM integrity and partially restoring vascular function [162,163,164,165]. The gene discussed is HPSE; the disease is neoplasm.